{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:54:36Z","timestamp":1791644076553,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.brainres.2012.04.032","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T09:06:10Z","timestamp":1335258370000},"page":"111-118","source":"Crossref","is-referenced-by-count":207,"special_numbering":"C","title":["Buspirone: What is it all about?"],"prefix":"10.1016","volume":"1461","author":[{"given":"C.","family":"Loane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2012.04.032_bb0465","series-title":"Frontiers of Neurology and Neuroscience Research","first-page":"4","article-title":"Pre- and postsynaptic feedback mechanisms in central dopaminergic neurons","author":"Aghajanian","year":"1974"},{"key":"10.1016\/j.brainres.2012.04.032_bb0470","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/WNF.0b013e3182227736","article-title":"Duloxetine-induced nocturnal bruxism resolved by buspirone: case report","volume":"34","author":"Albayrak","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-199902000-00014","article-title":"Buspirone: future directions","volume":"19","author":"Apter","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0163-7258(00)00083-8","article-title":"The psychobiology of anxiolytic drug. Part 2: pharmacological treatments of anxiety","volume":"88","author":"Argyropoulos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.brainres.2012.04.032_bb0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jns.2007.04.019","article-title":"Treatment of spinocerebellar ataxia with buspirone","volume":"260","author":"Assadi","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainres.2012.04.032_bb0030","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2012.04.032_bb0035","first-page":"309","article-title":"Buspirone therapy for elderly patients with anxiety or depressive neurosis","volume":"51","author":"Bohm","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00019442-199622430-00011","article-title":"Buspirone vs Haliperidol: a double-blind trial for agitation in a nursing home population with Alzhiemer's disease","volume":"4","author":"Cantillon","year":"1996","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881107068066","article-title":"Lack of deleterious effects of buspirone on cognition in healthy male volunteers","volume":"21","author":"Chamberlain","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(88)91988-5","article-title":"Buspirone in treatment of agitated demented patient","volume":"1","author":"Colenda","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.brainres.2012.04.032_bb0060","first-page":"361","article-title":"Alcohol and psychiatric comorbidity","volume":"16","author":"Cornelius","year":"2003","journal-title":"Recent Dev. Alcohol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10578-010-0193-2","article-title":"Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial","volume":"41","author":"Davari-Ashtiani","year":"2010","journal-title":"Child Psychiatry Hum. Dev."},{"key":"10.1016\/j.brainres.2012.04.032_bb0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainres.2012.04.032_bb0075","first-page":"375","article-title":"Effects of buspirone on dopamine dependent behaviours in rats","volume":"51","author":"Dhavalshankh","year":"2007","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004714-198608000-00002","article-title":"Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials","volume":"6","author":"Erwin","year":"1986","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainres.2012.04.032_bb0090","first-page":"25","article-title":"Effects of buspirone on operant behavior of laboratory rats and cynomolgus monkeys","volume":"43","author":"Geller","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003495-198632020-00002","article-title":"Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic","volume":"32","author":"Goa","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.brainres.2012.04.032_bb0100","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0306-4522(99)00211-0","article-title":"Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions","volume":"93","author":"Gobert","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2012.04.032_bb0105","first-page":"90","article-title":"Buspirone\u2013a new antianxiety agent not chemically related to any presently marketed drugs [proceedings]","volume":"15","author":"Goldberg","year":"1979","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.brainres.2012.04.032_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hup.429","article-title":"Platelet 5-HT2A-receptor-mediated induction of aggregation is not altered in major depression","volume":"17","author":"Gomez-Gil","year":"2002","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/ajp.150.5.819","article-title":"Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive\u2013compulsive disorder","volume":"150","author":"Grady","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0002-9343(86)90329-3","article-title":"Investigation of the abuse liability of buspirone in alcohol-dependent patients","volume":"80","author":"Griffith","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.brainres.2012.04.032_bb0125","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/00004583-199510000-00009","article-title":"Buspirone in ADHD with ODD","volume":"34","author":"Gross","year":"1995","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.pnpbp.2004.08.003","article-title":"Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy","volume":"28","author":"Haleem","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FBP.0b013e3280dec67f","article-title":"Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study","volume":"18","author":"Haleem","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00019442-199300130-00010","article-title":"Buspirone in the management of agitation and aggression associated with dementia","volume":"1","author":"Herrmannm","year":"1993","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1176\/ajp.152.5.812a","article-title":"Efficacy of buspirone in the treatment of dementia with aggression","volume":"152","author":"Holzer","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0150","first-page":"17","article-title":"Drug therapies for tardive dyskinesia: part 2","volume":"49","author":"Howland","year":"2011","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.brainres.2012.04.032_bb0475","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.pbb.2011.04.007","article-title":"Attenuation of apomorphine-induced sensitization by buspirone","volume":"99","author":"Ikram","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainres.2012.04.032_bb0160","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1176\/ajp.145.10.1285","article-title":"An open trial of buspirone in obsessive\u2013compulsive disorder","volume":"145","author":"Jenike","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0165","first-page":"13","article-title":"Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder","volume":"52","author":"Jenike","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","article-title":"Buspirone in the treatment of levodopa induced dyskinesias","volume":"54","author":"Kleedorfer","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","article-title":"A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms","volume":"7","author":"Lader","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0180","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1526-4610.2005.05181.x","article-title":"Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study","volume":"45","author":"Lee","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.brainres.2012.04.032_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/NRE-2005-20405","article-title":"Treatment of agitation following traumatic brain injury: a review of the literature","volume":"20","author":"Levy","year":"2005","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.brainres.2012.04.032_bb0190","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archneur.1995.00540340074015","article-title":"Use of buspirone for treatment of cerebellar ataxia. An open-label study","volume":"52","author":"Lou","year":"1995","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198608000-00004","article-title":"Buspirone, Parkinson's disease, and the locus ceruleus","volume":"9","author":"Ludwig","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1530-0277.1996.tb01644.x","article-title":"Buspirone in the treatment of alcohol dependence: a placebo-controlled trial","volume":"20","author":"Malec","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2012.04.032_bb0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/14734220510007914","article-title":"The wide spectrum of spinocerebellar ataxias (SCAs)","volume":"4","author":"Manto","year":"2005","journal-title":"Cerebellum"},{"key":"10.1016\/j.brainres.2012.04.032_bb0215","first-page":"56","article-title":"Acute effects of buspirone and alcohol on psychomotor skills","volume":"43","author":"Mattila","year":"1982","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","article-title":"Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive\u2013compulsive disorder","volume":"150","author":"McDougle","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0225","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/0006-2952(82)90712-2","article-title":"Striatal synaptosomal tyrosine hydroxylase activity. A model system for study of presynaptic dopamine receptors","volume":"31","author":"McMillen","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0028-3908(83)90240-X","article-title":"Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat","volume":"22","author":"McMillen","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2012.04.032_bb0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1523\/JNEUROSCI.03-04-00733.1983","article-title":"Dopamine receptor antagonism by the novel antianxiety drug, buspirone","volume":"3","author":"McMillen","year":"1983","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2012.04.032_bb0240","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1192\/S0007125000075292","article-title":"Buspirone augmentation of sertraline","volume":"166","author":"Menkes","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0245","first-page":"40","article-title":"Neurochemical effects of buspirone in rat hippocampus: evidence for selective activation of 5HT neurons","volume":"279","author":"Mennini","year":"1986","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.brainres.2012.04.032_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-002-1121-3","article-title":"Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat","volume":"163","author":"Mignon","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2012.04.032_bb0255","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00004714-199306000-00009","article-title":"Buspirone in the treatment of tardive dyskinesia","volume":"13","author":"Moss","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0260","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00213-006-0507-z","article-title":"An increased hypothermic response to buspirone in patients with major depression","volume":"188","author":"Navines","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2012.04.032_bb0265","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hup.862","article-title":"Hormonal response to buspirone is not impaired in major depression","volume":"22","author":"Navines","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0270","first-page":"289","article-title":"Hypothesis: a promising effect of 5-HT1A receptor agonists in alleviating motor symptoms in Parkinson's disease","volume":"4","author":"Nayebi","year":"2010","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1734-1140(10)70264-4","article-title":"Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats","volume":"62","author":"Nayebi","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.brainres.2012.04.032_bb0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/depr.3050020208","article-title":"Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors","volume":"2","author":"Norden","year":"1994","journal-title":"Depression"},{"key":"10.1016\/j.brainres.2012.04.032_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1176\/ajp.148.1.127","article-title":"Controlled comparison of buspirone and clomipramine in obsessive\u2013compulsive disorder","volume":"148","author":"Pato","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00004714-199410000-00005","article-title":"A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder","volume":"14","author":"Pecknold","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0295","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0006-3223(85)90194-5","article-title":"Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors","volume":"20","author":"Peroutka","year":"1985","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0300","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(88)90011-2","article-title":"5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization","volume":"11","author":"Peroutka","year":"1988","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.brainres.2012.04.032_bb0305","first-page":"175","article-title":"An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder","volume":"32","author":"Phillips","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.brainres.2012.04.032_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","article-title":"A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive\u2013compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0315","first-page":"8","article-title":"Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?","volume":"2","author":"Politis","year":"2010","journal-title":"BMC Med."},{"key":"10.1016\/j.brainres.2012.04.032_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-10-1","article-title":"Clinical application of stem cell therapy in Parkinson's disease","volume":"10","author":"Politis","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.brainres.2012.04.032_bb0485","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1100\/2011\/172893","article-title":"Serotonergic dysfunction in Parkinson's disease and its relevance to disability","volume":"11","author":"Politis","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.brainres.2012.04.032_bb0320","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0079-6123(10)84010-5","article-title":"Brain imaging after neural transplantation","volume":"184","author":"Politis","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.brainres.2012.04.032_bb0325","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2012.04.032_bb0330","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","article-title":"Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures","volume":"75","author":"Politis","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2012.04.032_bb0490","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2012.04.032_bb0345","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nbd.2011.05.009","article-title":"Serotonergic mediated body mass index changes in Parkinson's disease","volume":"43","author":"Politis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2012.04.032_bb0350","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin\/dopamine transporter ratio","volume":"26","author":"Politis","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2012.04.032_bb0495","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1126\/scitranslmed.3003391","article-title":"Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts","volume":"4","author":"Politis","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2012.04.032_bb0365","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0278-5846(99)00074-3","article-title":"Effects of buspirone on an animal model of tardive dyskinesia","volume":"23","author":"Queiroz","year":"1999","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0370","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00007611-199002000-00014","article-title":"Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety","volume":"83","author":"Rakel","year":"1990","journal-title":"South. Med. J."},{"key":"10.1016\/j.brainres.2012.04.032_bb0375","first-page":"11","article-title":"Pharmacology and neurochemistry of buspirone","volume":"43","author":"Riblet","year":"1982","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.brainres.2012.04.032_bb0380","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000284133","article-title":"Neuropharmacology of buspirone","volume":"17","author":"Riblet","year":"1984","journal-title":"Psychopathology"},{"key":"10.1016\/j.brainres.2012.04.032_bb0385","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0028-3908(91)90203-N","article-title":"Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats","volume":"30","author":"Rowlett","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2012.04.032_bb0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1754-4505.2009.00091.x","article-title":"Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: a case report","volume":"29","author":"Sabuncuoglu","year":"2009","journal-title":"Spec. Care Dentist."},{"key":"10.1016\/j.brainres.2012.04.032_bb0500","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00019442-199300110-00011","article-title":"Effects of buspirone on agitation associated with dementia","volume":"1","author":"Sakauye","year":"1993","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0405","first-page":"46","article-title":"New and emerging clinical uses for buspirone","volume":"12","author":"Schweizer","year":"1994","journal-title":"J. Clin. Psychiatry Monogr."},{"key":"10.1016\/j.brainres.2012.04.032_bb0410","first-page":"753","article-title":"Motor effects of buspirone: relationship with dopamine and serotonin in the striatum","volume":"15","author":"Shireen","year":"2005","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"10.1016\/j.brainres.2012.04.032_bb0415","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00004714-199404000-00007","article-title":"Buspirone's efficacy in organic-induced aggression","volume":"14","author":"Stanislav","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0505","series-title":"The Neurolobiology of the Nucleus Accumbens","first-page":"316","article-title":"Buspirone: An anxioselective drug with dopaminergic action","author":"Stanton","year":"1981"},{"key":"10.1016\/j.brainres.2012.04.032_bb0425","first-page":"3","article-title":"The uses of buspirone in psychiatry","volume":"12","author":"Sussman","year":"1994","journal-title":"J. Clin. Psychiatry. Monogr."},{"key":"10.1016\/j.brainres.2012.04.032_bb0430","first-page":"337","article-title":"Inhibition of aggressive behavior in rhesus monkeys by buspirone","volume":"5","author":"Tompkins","year":"1980","journal-title":"Res. Commun. Psychol. Psychiatry Behav."},{"key":"10.1016\/j.brainres.2012.04.032_bb0510","first-page":"708","article-title":"Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication","volume":"151","author":"Trouillas","year":"1995","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.brainres.2012.04.032_bb0440","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0773.1991.tb01289.x","article-title":"Molecular basis of buspirone's anxiolytic action","volume":"69","author":"Tunnieliff","year":"1991","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0445","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-0327(96)00030-4","article-title":"Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia","volume":"39","author":"Van Ameringen","year":"1996","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.brainres.2012.04.032_bb0450","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","article-title":"Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study","volume":"58","author":"van Vliet","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainres.2012.04.032_bb0455","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00498834","article-title":"Dopaminergic neurons: an invivo system for measuring drug interactions with presynaptic receptors","volume":"296","author":"Walters","year":"1976","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.brainres.2012.04.032_bb0460","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbadis.2008.09.009","article-title":"Targets for neuroprotection in Parkinson's disease","volume":"1792","author":"Yacoubian","year":"2009","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899312007263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899312007263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T12:03:32Z","timestamp":1594037012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899312007263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":91,"alternative-id":["S0006899312007263"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2012.04.032","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}